A new study shows that delivery of gene therapy to correct the gene mutations that cause CLN2 disease, or Batten disease, directly into the cerebrospinal fluid (CSF) has potential therapeutic effects.
Sandoz invests $90m to build a biosimilar centre in Slovenia – Pharmaceutical Technology
The increase in production and development of biosimilars is part of Sandoz’s 2022 Act4Biosimilars initiative to increase the adoption of biosimilars by 30% in over